Literature DB >> 33144456

Predicting Biochemical Failure in Irradiated Patients With Prostate Cancer by Tumour Volume Measured by Multiparametric MRI.

Benedict Oerther1, Moritz V Buren2, Christina M Klein3,4, Simon Kirste3,4, Nils H Nicolay3,4, Tanja Sprave3,4, Simon Spohn3,4, Deepa Darshini Gunashekar4,5, Leonard Hagele4,5, Lars Bielak4,5, Michael Bock4,5, Anca-L Grosu3,4,6, Fabian Bamberg7, Matthias Benndorf7, Constantinos Zamboglou3,4,6.   

Abstract

BACKGROUND/AIM: We examined the prognostic value of intraprostatic gross tumour volume (GTV) as measured by multiparametric MRI (mpMRI) in patients with prostate cancer following (primary) external beam radiation therapy (EBRT). PATIENTS AND METHODS: In a retrospective monocentric study, we analysed patients with prostate cancer (PCa) after EBRT. GTV was delineated in pre-treatment mpMRI (GTV-MRI) using T2-weighted images. Cox-regression analyses were performed considering biochemical failure recurrence-free survival (BRFS) as outcome variable.
RESULTS: Among 131 patients, after a median follow-up of 57 months, biochemical failure occurred in 27 (21%). GTV-MRI was not correlated with % of positive biopsy cores, Gleason score and initial PSA (all r<0.2) and only moderately correlated with cT stage (r=0.32). In univariate analysis, cT stage, Gleason score and GTV-MRI were higher in subjects with shorter BRFS (p<0.05). GTV-MRI remained a significant predictor for BRFS in multivariate analyses, independent of Gleason score and cT stage.
CONCLUSION: GTV, defined using mpMRI, provides incremental prognostic value for BRFS, independent of established risk factors. This supports the implementation of imaging-based GTV for risk-stratification, although further validation is needed. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  MRI; Prostate cancer; radiation oncology; tumour volume

Mesh:

Substances:

Year:  2020        PMID: 33144456      PMCID: PMC7811616          DOI: 10.21873/invivo.12187

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  39 in total

1.  Pattern of relapse and dose received by the recurrent intraprostatic nodule in low- to intermediate-risk prostate cancer treated with single fraction 19 Gy high-dose-rate brachytherapy.

Authors:  Lucas C Mendez; Ananth Ravi; Hans Chung; Chia-Lin Tseng; Matt Wronski; Moti Paudel; Merrylee McGuffin; Patrick Cheung; Andrew Loblaw; Gerard Morton
Journal:  Brachytherapy       Date:  2017-11-11       Impact factor: 2.362

2.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate.

Authors:  J E McNeal; A A Villers; E A Redwine; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1990-09-15       Impact factor: 6.860

3.  Biological determinants of cancer progression in men with prostate cancer.

Authors:  T A Stamey; J E McNeal; C M Yemoto; B M Sigal; I M Johnstone
Journal:  JAMA       Date:  1999-04-21       Impact factor: 56.272

Review 4.  Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review.

Authors:  Klaus Eichler; Susanne Hempel; Jennifer Wilby; Lindsey Myers; Lucas M Bachmann; Jos Kleijnen
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

5.  Diffusion radiomics analysis of intratumoral heterogeneity in a murine prostate cancer model following radiotherapy: Pixelwise correlation with histology.

Authors:  Yu-Chun Lin; Gigin Lin; Ji-Hong Hong; Yi-Ping Lin; Fang-Hsin Chen; Shu-Hang Ng; Chun-Chieh Wang
Journal:  J Magn Reson Imaging       Date:  2017-02-08       Impact factor: 4.813

6.  An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk.

Authors:  Scott G Williams; Gillian M Duchesne; N Kumar Gogna; Jeremy L Millar; Tom Pickles; Gary R Pratt; Sandra Turner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-03-10       Impact factor: 7.038

7.  Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence.

Authors:  Darko Pucar; Hedvig Hricak; Amita Shukla-Dave; Kentaro Kuroiwa; Marija Drobnjak; James Eastham; Peter T Scardino; Michael J Zelefsky
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-01       Impact factor: 7.038

8.  Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study.

Authors:  Elnasif Arrayeh; Antonio C Westphalen; John Kurhanewicz; Mack Roach; Adam J Jung; Peter R Carroll; Fergus V Coakley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

9.  Comparison of 68Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology.

Authors:  Constantinos Zamboglou; Vanessa Drendel; Cordula A Jilg; Hans C Rischke; Teresa I Beck; Wolfgang Schultze-Seemann; Tobias Krauss; Michael Mix; Florian Schiller; Ulrich Wetterauer; Martin Werner; Mathias Langer; Michael Bock; Philipp T Meyer; Anca L Grosu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

10.  3 Tesla multiparametric MRI for GTV-definition of Dominant Intraprostatic Lesions in patients with Prostate Cancer--an interobserver variability study.

Authors:  Hans Christian Rischke; Ursula Nestle; Tobias Fechter; Christian Doll; Natalja Volegova-Neher; Karl Henne; Jutta Scholber; Stefan Knippen; Simon Kirste; Anca L Grosu; Cordula A Jilg
Journal:  Radiat Oncol       Date:  2013-07-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.